KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Gross Profit (2016 - 2025)

Neogenomics (NEO) has disclosed Gross Profit for 16 consecutive years, with $83.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 7.88% year-over-year to $83.3 million, compared with a TTM value of $314.3 million through Dec 2025, up 8.34%, and an annual FY2025 reading of $314.3 million, up 8.34% over the prior year.
  • Gross Profit was $83.3 million for Q4 2025 at Neogenomics, up from $80.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $83.3 million in Q4 2025 and bottomed at $38.2 million in Q1 2022.
  • Average Gross Profit over 5 years is $61.2 million, with a median of $61.1 million recorded in 2023.
  • Peak annual rise in Gross Profit hit 89.21% in 2021, while the deepest fall reached 21.23% in 2021.
  • Year by year, Gross Profit stood at $45.3 million in 2021, then grew by 25.56% to $56.8 million in 2022, then increased by 18.94% to $67.6 million in 2023, then rose by 14.31% to $77.3 million in 2024, then grew by 7.88% to $83.3 million in 2025.
  • Business Quant data shows Gross Profit for NEO at $83.3 million in Q4 2025, $80.4 million in Q3 2025, and $77.3 million in Q2 2025.